7 citations
,
November 2021 in “JAAD Case Reports” Mogamulizumab can cause hair loss and skin rashes.
13 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.
56 citations
,
July 2014 in “PLoS ONE” Midazolam reduces PTSD-like behavior in rats by acting on specific brain receptors.
July 2003 in “Current Prostate Reports” Combining different treatments may be needed to effectively manage chronic prostatitis.
3 citations
,
January 2019 in “Therapeutic advances in urology” WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
January 2026 in “E3S Web of Conferences” Silver nanoparticles from Mitracarpus scaber protect the liver and reduce prostate enlargement.
January 2026 in “International Journal of Biological Macromolecules”
3 citations
,
April 2010 in “Clinical Neuropharmacology” Finasteride helps treat eyelid spasms.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” CD101 is highly effective in treating dermatophytosis in guinea pigs.
2 citations
,
January 2022 in “Indian dermatology online journal” Dermoscopy may not show hookworms clearly, and comparing it with tissue studies could improve diagnosis accuracy for skin conditions caused by parasites.
3 citations
,
January 2024 in “3 Biotech”
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
8 citations
,
January 2021 in “Journal of Pharmaceutical Investigation” June 2009 in “Chin J Endocr Surg” Finasteride with antibiotics is more effective for treating hemospermia than antibiotics alone.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for managing PCOS-related risks.
4 citations
,
October 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.
12 citations
,
January 2018 in “Journal of Drug Delivery Science and Technology” The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
Combining hydroxychloroquine and pimecrolimus can effectively treat hair loss from discoid lupus.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
10 citations
,
October 2023 in “Mycoses” White Piedra mainly affects young women and is linked to hair-related factors.
2 citations
,
May 2021 in “Neuropathology & applied neurobiology/Neuropathology and applied neurobiology” Correct diagnosis and treatment are crucial for effective management of lipid storage myopathies.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
21 citations
,
July 2014 in “Antimicrobial Agents and Chemotherapy” Finasteride effectively prevents biofilm formation and treats preformed biofilms, but requires high doses.
January 2024 in “Pharmaceutical medicine” Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.
474 citations
,
January 2012 in “Chemistry & biology” Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
7 citations
,
March 2018 in “Psychiatry and Clinical Psychopharmacology” Valproate can cause brain swelling with high ammonia levels, possibly underreported, especially in psychiatric patients.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.